HPV types in young New Zealand women with high grade cervical cell abnormalities

Not Applicable

Completed

• Conditions: cervical cell abnormality; Cancer - Cervical (cervix)

• Registration Number: ACTRN12618001414202
• Lead Sponsor: niversity of Otago, Christchurch

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-08-24
• Study Completion: 2020-09-10
• Last Update Posted: 16 February 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 154

Inclusion Criteria

Women aged 20-24 years.
Referred to colposcopy (at a participating centre) with an abnormal smear.

Exclusion Criteria

None

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The prevalence of high risk vaccine-type human papillomavirus genotypes (either HPV 16 or 18 or both) in young women (aged 20-24 years) with high grade histology (e.g., CIN2 or CIN3).[HPV genotype analysis for each participant will be undertaken on the cytology taken at the initial colposcopic assessment. HPV genotype prevalence will be assessed once all participants have been recruited - approximately 12 months after first enrolment.]

Secondary Outcome Measures

Name	Time	Method
HPV vaccination status as assessed by data-linkage to the National Immunisation Register.[HPV vaccination status for each participant will be requested following their initial colposcopic assessment. Analysis of the overall group will be assessed once all participants have been recruited - approximately 12 months after first enrolment.];The prevalence of high risk vaccine-type human papillomavirus genotypes (either HPV 16 or 18 or both) compared with (1) other high risk non-vaccine genotypes and (2) co-infection with vaccine-type HPV genotypes and high risk non-vaccine genotypes, in young women (aged 20-24 years) with LOW grade histology (e.g., CIN1)..[HPV genotype analysis for each participant will be undertaken on the cytology taken at the initial colposcopic assessment. HPV genotype prevalence will be assessed once all participants have been recruited - approximately 12 months after first enrolment.]